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A B S T R A C T
Scarring/Opacity on the surface of the eye and vascularisation following infectious diseases, inﬂammation and
corneal trauma are often a leading cause of blindness. The ‘gold standard’ treatment to prevent corneal scarring
is the application of amniotic membrane (AM) to the ocular surface in the acute stage of injury. Although
clinically eﬀective, the use of the AM is associated with biological variability and unpredictable responses.
Potential health risks including disease transmission, signiﬁcant ethical issues surrounding the tissue donation
process and stringent regulations/storage conditions, preclude widespread use. Consequently, there is a demand
for the development of a new, synthetic alternative, that is stable at room temperature, capable of protecting the
wound and has the capacity to deliver anti-scarring and anti-inﬂammatory mediators. Here we have developed a
micro-structured ﬂuid gel eye drop, to deliver a potent anti-scarring molecule, decorin. We have compared the
release of decorin from the formulated dressing to a typical gel ﬁlm, demonstrating enhanced release for the
ﬂuid gel eye-drops. Therefore, we have investigated the eﬀect of the ﬂuid gel system in 2D human corneal
ﬁbroblast culture models, as well as shown the retention of the gellan ﬂuid gel in an in vivo rat model. At the
same time the eﬃcacy of the ﬂuid gel eye drop was studied in an organ culture model, whereby the ﬂuid gel
containing decorin, signiﬁcantly (P < 0.05) increased re-epithelialisation within 4 days of treatment.
1. Introduction
The ocular surface is a highly organized and delicate structure,
comprising the cornea and conjunctival tissues. It's avascular nature
and the intricately aligned layers of collagen ﬁbrils are responsible for
the optical transparency of the cornea [1]. Various diseases, nutritional
deﬁciency or traumatic injury can lead to: corneal ulceration, stromal
loss, tissue remodelling, scarring and limbal corneal epithelial stem
failure, resulting in recurrent ocular surface breakdown. This increases
the risk of secondary infection associated with loss of biomechanical
integrity such as: corneal distortion, perforation and irreversible
blindness [2]. Generally, when the cornea becomes damaged, the tissue
is typically able to repair itself, resulting in normal function. However,
in cases where it becomes exposed to pathogenic microorganisms, this
does not occur. Breaches in the corneal epithelium, often observed as a
consequence of prolonged contact lens wear, enable bacterial invasion
into the corneal stroma leading to ampliﬁed innate immune responses;
characterized by heightened inﬂammatory cell recruitment, in an at-
tempt to eradicate infection. Concurrent up-regulation of various
growth factors such as transforming growth factor (TGF-β1), and pla-
telet-derived growth factors (PDGF) stimulate the tissue repair process
including corneal stromal keratocyte activation, myodiﬀerentiation,
and laying down of extracellular matrix (ECM) [3,4]. This combination
of growth factors triggers ﬁbrotic pathways leading to further disrup-
tion of the highly ordered collagen ﬁbrils, and ultimately drives scar
formation. The presence of scar tissue, primarily composed of irregu-
larly deposited collagenous matrix, with or without corneal neovascu-
larization, results in loss of corneal clarity and irreversible loss of sight.
Thus, once the acute phase of injury has subsided, surgical removal of
visually disabling scar tissue is required, with corneal transplantation
remaining the mainstay.
The current ‘gold standard’ treatment in preventing the formation of
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corneal scars and minimizing tissue damage, is the application of de-
nuded amniotic membrane (AM) to the ocular surface; throughout the
acute phase of injury [5]. The bandaging eﬀect of the amnion dampens
cascading of ﬁbrogenic signalling during the various stages of healing
[6–8], as well as providing anti-ﬁbrotic/anti-inﬂammatory factors to
the wound site, to assist healing [9,10]. Although clinically eﬀective,
the use of AM is typically limited due to reproducibility/repeatability
depending on the inter- and intra-amnion variability. Furthermore, the
technique requires additional surgery, as reapplication after 2–3 weeks
is needed. The widespread use of AM has been hindered, as it is highly
regulated and requires very specialised storage conditions. This is also
coupled with signiﬁcant ethical issues surrounding the tissue donation
process, and potential health risks such as disease transmission. As such
the drive towards alternative treatment strategies including the devel-
opment of amniotic membrane extract drops [11,12], has been sought.
Lyophilized amniotic membrane extract is powdered and reconstituted
with saline (0.9% NaCl). The treatment is applied directly to the ocular
wound, delivering healing factors to the site of trauma. Here the
duration of therapy is guided by the individual healing response.
However, to date, no technology has matched or replaced the ther-
apeutic capability of AM products, with regards to surface healing re-
sponses.
Historically the most common forms of ocular therapy are eye drops
systems, for their ease of application and direct delivery to the active
site. However, typically such systems lead to pulsed release mechan-
isms, as a consequence to rapid elimination through lid overﬂow and
drainage through the nasolacrimal duct [13]. As a result of poor re-
tention, much eﬀort has been placed into engineering novel methods of
extending residence times upon the ocular surface. Gellan gum has been
at the forefront of this drive, its inherent mucoadhesive properties aid
adsorption to the cornea, binding the water, and prolonging the re-
sidence of the therapeutic [14]. As such gellan has been used in many
eye drop formulations, commonly as a viscosity modiﬁer in very low
concentrations (< 0.1%). Unfortunately, the timescales required for
suﬃcient bioavailability/eﬃcacy is still not met using topical eye
drops. This has led to a considerable body of work focusing on in situ
gelation of gellan based ophthalmic solutions, with the intention of
controlled release/delivery [15]. In such cases solutions are applied to
the eye where gelation is mediated through pH [16], temperature [17],
or salt ions found within the tear ﬂuid [18]. However, many gels
formed in this manner have alterations to the polymer backbone or
secondary co-polymers, providing the necessary chemistries for me-
chanical stability or delivery [19–21]. However, the multiple compo-
nents of which many are not currently FDA approved prevents many of
the systems from being translated through to the clinic. Therefore, there
remains a clear need for systems that previously undergone regulatory
approval, where by manipulation of the microstructure in a chemically
inert way gives rise to functional material properties.
Fluid or shear gels are a prime example of a system where control
over the processing has led to microstructures which enhance the bulk
properties [22]. Fluid gels, unlike solutions with added viscosity
modiﬁers are micro-particulate suspensions produced by applying a
constant mechanical separation process (shear ﬁeld) during the sol-gel
process [23]. This results in a system where the chemical composition
of the components remains unchanged, but the physical properties can
be controlled; thus providing a direct route to translation [24]. Vis-
coelastic behaviours arise through weak structuring between particles,
as a function of the microstructure formed during processing
[23,25,26]. This gives solid-like behaviour at rest (like in situ gels) but
can ﬂow on manipulation to slowly be eliminated over time. Further-
more, unlike previously reported micro gel systems [27,28], the gelled
micro-particles are formed through a nucleation and growth me-
chanism, while the applied shear limits the degree of long ranged or-
dering [23]. Therefore, rate and extent of the ordering during the
shearing process ultimately dictates the degree of inter-particle struc-
turing and ability to form reversible particulate to continuous networks
[29].
This study seeks to control the microstructure of gellan gum hy-
drogels, in order to produce a novel topical ocular therapy that can
dynamically invert through solid-liquid-solid transitions during the
natural blinking mechanism of the eye. As such an ocular bandage can
be achieved in the form of a topical eye drop, with the ability to deliver
actives whilst retaining a high degree of retention upon the surface.
Therefore, a comparison of the release properties has been made be-
tween two micro-structured gels: quiescently formed gels (equivalent to
in situ gels reported in literature) and the ﬂuid gels, subsequently
moving on to describing its ability to aid wound healing in both in vitro
and ex vivo models. The work uses a potent anti-scarring molecule
(decorin), present in AM, as the active ingredient. Decorin, is a leucine
rich glycoprotein that attenuates ﬁbrotic scarring by sequestering
TGFβ1&2, directly interacting with collagen ﬁbrils and limiting ﬁ-
brillogenesis [30,31]. Previously, decorin has been shown to reduce
scarring in animal models for: intraocular pathologies including glau-
coma and proliferative vitreoretinopathy [32], together with brain in-
jury, spinal cord injury [33] and inﬂammatory hydrocephalus [34].
Although highly eﬀective in scar reduction, decorin is delivered in
systems that cannot be sustained upon the surface of the cornea long
enough to demonstrate a therapeutic eﬀect. Therefore, this work de-
monstrates the enhanced bioactivity and eﬃcacy of decorin from ﬂuid
gels as a potential topical treatment in ocular diseases.
2. Materials and methods
2.1. Materials
Low acyl gellan gum (Kelco Gel ™) was kindly donated by Azelis,
UK, sodium chloride was purchased from Sigma-Aldrich (UK), and
Galacorin (decorin) in PBS – 4.76mg/ml was purchased from Catalant,
USA.
2.2. Preparation of gellan delivery devices
2.2.1. Gellan ﬁlms
Gellan ﬁlms were produced by adding low acyl gellan gum (gellan)
at a concentration of 2% (w/v) to MilliQ water at 90 °C while stirring.
The resultant solution was cast on plastic polystyrene dishes
(10 cm×10 cm) and left to cool for 10min. The cast gels were further
dried using an oven (VacuTherm, UK) at 50 °C for 17 h. Films con-
taining decorin were prepared through the addition of the protein in
PBS to the gellan sol at 60 °C to a ﬁnal concentration of 0.24mg/ml
before casting the ﬁlms in the plastic polystyrene moulds.
2.2.2. Gellan ﬂuid gels
Fluid gels were prepared by adding low acyl gellan gum (gellan) at a
concentration of 1% (w/v) to MilliQ water at 90 °C whilst stirring. Once
fully dissolved the hydrocolloid solution was cooled to 60 °C, and
subsequently cooled further after being loaded into an AR-G2
Rheometer (TA Instruments Ltd, UK) at 1 °C/min whilst being sheared
at a shear rate of 450/s using a cup and vane geometry (cup: 35mm
diameter, vane: 28 mm diameter). Upon reaching a temperature of
40 °C, decorin (Galacorin) was added to a ﬁnal concentration of
0.24mg/ml. Further crosslinker (NaCl) was then added at concentra-
tions of 0.05, 0.1 and 0.2M; resulting in ﬁnal concentrations of 0.9%
w/v gellan, 2.5, 5 and 10mM NaCl. Shear viscosity was monitored
during ﬂuid gel production. The onset of gelation was identiﬁed at the
temperature when a 0.08% change in viscosity was observed.
2.3. Dynamic oscillatory rheology
The structure and particle interactions of the ﬂuid gels were eluci-
dated by dynamic oscillatory measurements on a AR-G2 Rheometer (TA
Instruments Ltd, UK) using a sandblasted parallel plate geometry (1mm
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gap, 40mm diameter). Dynamic storage modulus (G’) was determined
at constant frequency of 1 Hz at a range of 0.1–100% strain.
2.4. Decorin release
Decorin release from the hydrogel systems was conducted in phos-
phate buﬀered saline (PBS) and evaluated using a decorin ELISA (R&D,
UK), following instructions from the manufacturer. In brief, dried gellan
ﬁlms were prepared to ﬁt in a 6 well plate, containing a total 0.24mg of
decorin. Films and ﬂuid gel (1 ml containing 0.24mg/ml of decorin)
were added to the well of a 6 well plate. Following, PBS (4ml) was
pipetted into the well so that the hydrogels were completely sub-
merged. In the case of the ﬂuid gel, precaution was taken not to disrupt
the gelled phase, preventing break-up of the gel and the need for dia-
lysis tubing (Fig. s1). The samples were incubated at 37 °C and aliquots
(0.5 ml) removed at each time point (5, 10, 15, 20, 25, 30, 45, 60, 75,
90, 105, 120, 150, 180, 210, 240min), replenishing the volume in each
case with fresh PBS. Active concentration was subsequently analysed
using ELISA with all experiments undertaken in triplicate.
2.5. Fluid gel transparency measurements
Measurements of optical transparency were performed using a CE
7500 double beam UV/visible spectrophotometer. Fluid gels were
added into 1mm cuvettes; transmittance (%) at 600 nm was recorded.
The instrument was zeroed using sterile MilliQ water as a control. Three
tests were performed and results averaged. Standard error bars are
plotted as the standard deviation.
2.6. In vitro studies
2.6.1. Corneal ﬁbroblast culturing
Corneal ﬁbroblasts (CFs) were cultured in Dulbecco's Modiﬁed
Eagles Medium supplemented with 10% FBS (Sigma Aldrich, UK), 2.5%
Penicillin Streptomycin (Sigma Aldrich, UK) and 2.5% L-Glutamine
(Sigma Aldrich, UK). Corneal ﬁbroblasts were trypsinised and seeded in
6 well plates at a seeding density of 2×105 cells/ml and left to attach
to for 16 h, 10 ng/ml TGF-β1 was added to the cultures to diﬀerentiate
primary ﬁbroblasts to myoﬁbroblasts for 7 days. Fluid gels with and
without decorin were added to the cultures. Cell viability and metabolic
activity were assessed using Calcein AM and MTT respectively.
Collagen deposition was determined using Sirius red staining and the
hydroxyproline assay.
2.6.2. Live/dead (Calcein AM/PI) assay
Corneal ﬁbroblasts were cultured as in section 2.5.1. Viability was
assessed using Calcein AM (50 μg/ml) and propidium iodide (PI,
100 μg/ml). The dyes were added to the cultures and left for 5min in an
incubator. The stained cultures were observed using a ﬂuorescence
microscope (Carl Zeiss Ltd, Hertfordshire, UK) and images of live and
dead cells stained green and red respectively were captured using a
digital camera (Powershot G5, Canon UK Ltd, Surrey, UK).
2.6.3. Metabolic activity (MTT) assay
Corneal ﬁbroblasts were cultured as in section 2.5.1. Thiazolyl blue
tetra-zolium bromide (MTT) (5mg/ml) was added to the cell cultures
and incubated for 4 h at 37 °C to assess cell metabolic activity. MTT is
reduced to purple formazon crystals in living cells by mitochondrial
reductase. The formazon crystals were dissolved using HCl-isopropanol
solution and read within the hour at 620 nm on a plate reader (Glomax
Multi Detection System Plate reader – Promega).
2.6.4. Sirius red assay
Corneal ﬁbroblast cultures were washed with phosphate buﬀered
saline (PBS) and ﬁxed with Bouin's ﬂuid for 1 h. Fixed cultures were
washed with distilled water and left to air dry for 15min. Sirius red
solution (1mg/ml) prepared in saturated picric acid, was added to the
cultures and left on a plate shaker for 1 h at room temperature. Excess
dye was aspirated and the stained cultures were washed with hydro-
chloric acid (0.01 N). Images were taken using an inverted light mi-
croscope. For semi-quantitative analysis, the stain was lifted using
NaOH (0.1 N). The dissolved dye was transferred to a 96 well plate and
read using a plate reader (Glomax Multi Detection System Plate reader -
Promega) at an optical density (OD) 550 nm against NaOH (0.1 N)
blank.
2.7. Ex-vivo studies
2.7.1. In situ eye drop structuring
Structuring upon the ocular surface was tested on freshly enucleated
pig eyes. 4 pig eyes were sourced from a local abattoir (Coventry, UK)
and used on the same day that they were collected. Eyes were re-
frigerated between collection and use. The eyes were washed with
Dulbecco's Modiﬁed Eagles Medium (DMEM) and placed in a plate with
the eyes facing upwards. 150 μl of the ﬂuid gel was placed on the
surface of the eyes; PBS was used as a control. The eyes were photo-
graphed (Nikon, D7100, UK) to observe spreading over time.
2.7.2. Organ culture model for wound healing
The eﬃciency of the ﬂuid gel with and without decorin in an ex-vivo
organ culture model of corneal wound healing. Eight-to ten-week old,
male, 175–200 g, Sprague Dawley rats (Charles River, Kent, UK), Rats
were sacriﬁced by exposure to increasing concentrations of CO2 at the
Biomedical Services Unit at the University of Birmingham
(Birmingham, UK) in accordance with the Home Oﬃce guidelines set
out in the 1986 Animal Act (UK). Wounding was performed within 1 h
of sacriﬁce. The globe was then irrigated with PBS. A full thickness
5mm corneal abrasion was produced using a 15° micro-scalpel. The
globes were enucleated, ﬁxed in 6 well plates and treated with 40 μl of
ﬂuid gel with and without decorin (n= 4). The globes were topped up
with DMEM 2.5% Penicillin Streptomycin and 2.5% L-Glutamine.
Specimens were maintained at 37 °C and 5% CO2 for 48 h. For H&E
staining the eyes were removed and ﬁxed in 4% formaldehyde. The
corneas were dissected, washed in PBS for 30min and cryo-protected
by sequential immersion in increasing concentrations of sucrose solu-
tions in PBS (10%, 20% and 30% v/w) at 4 °C. The corneas were then
embedded in Tissue-Tek® O.C.T.™ compound (Sakura Finetek UK Ltd,
Thatcham, UK) and frozen in embedding moulds with the dimensions of
22mm×22mm square×20mm deep. The corneas were placed in a
convex position, while pushed against one of the block walls Solidiﬁed
embedding blocks were mounted on a chuck in a Bright cryostat (Bright
Instruments, Luton, UK), radially sectioned (15 μm thick; 12.5° angle of
blade), adhered onto Xtra™ adhesive slides (Surgipath, Peterborough,
UK), allowed to dry, and stored at ̶ 20 °C before staining. Sections are
diﬀerentiated in 1% v/v acid-alcohol solution (1% HCl in 70% ethanol)
for 5 s which removes the excess staining, rinsed in running tap water
for 1min, blued in 0.1% w/v sodium bicarbonate (NaHCO3; VWR
International Ltd) for 2min, and then rinsed in running tap water and
immersed×2 in 95% ethanol for 1.5 min. This was followed by ex-
posure to the cytoplasmic counterstain in alcoholic Eosin Y solution
(0.5% w/v in acidiﬁed 90% ethanol) for 1min. Sections were then
dehydrated through an ascending series of alcohol solutions: 70%, 90%
and 2 changes of 100% ethanol and cleared in 3 changes of Histoclear,
and ﬁnally mounted in Vectamount™ permanent medium (Vector
Laboratories). The histological images were captured using Axioplan 2
microscope equipped with an Axiocam HRc lens running Axiovision
software Version 4.8.2.0 (Zeiss).
2.8. In vivo studies
2.8.1. Gellan ﬂuid gel retention on rat corneas
Rats were anesthetised by intraperitoneal injection of a mixture of
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ketamine hydrochloride (2.4 ml of 100mg/ml), medetomidine hydro-
chloride (1.0 ml of 1.0mg/ml), and injectable water (9.0 ml) at a dose
of 3.0 ml/kg body weight. Six rats (n= 12 eyes) received 4 diﬀerent
eye-drop formulations (3 eyes/treatment)). Having received 40 μl of the
respective eye drop formulation, anterior segment OCT images were
acquired immediately (0 h) and repeated every 30min while anaes-
thetised for up to 2 h using a Spectralis HRA3 confocal scanning laser
ophthalmoscope (Heidelberg Engineering, Heidelberg, Germany). Rats
were killed at the end of the 2 h by cervical dislocation. Images were
analysed using ImageJ software (National Institutes of Health,
Maryland, USA) at 3 diﬀerent regions of the corneal surface (45°
(nasal), 90° (central), 135° (temporal)).
3. Results
3.1. Formation of gellan gum ﬁlms and ﬂuid gels
Gellan gum may easily be gelled into a rehydratable, optically
transparent structure. Casting of a 2% w/v solution and cooling
to< 37 °C forms a gel through ordering of the biopolymer from random
coil to structured helices [35]. These cast gels may be further processed
via a drying stage at 50 °C, resulting in transparent ﬁlms of thickness
25–30 μm that can be rehydrated immediately prior to use (Fig. 1B).
Molecules such as decorin may be absorbed into the structure in a facile
manner, and undergoing release when placed in an aqueous environ-
ment. The optically inert nature of the gellan gel means that it is perfect
for use as an eye dressing, however, the irregular contouring of the
ocular surface and gel dehydration make the material impractical for
use on the cornea. By modifying the processing conditions, it is possible
to make a substrate with similar optical properties, that can be simply
delivered onto the surface of the cornea, in the form of an eye drop.
Existing topical drugs such as eye drops, although commonly used,
are relatively ineﬃcient as drug delivery systems. This is due to the
high drop to pre-corneal ratio, where eye drops often range from 25 to
50 μl and the pre-corneal volume in humans is ca. 7 μl [36]. As such,
bio-eﬃciency is often very low as ﬁrstly, the excess volume is quickly
cleared as previously discussed, followed by rapid clearance of the pre-
corneal tear ﬁlm (approximately 20%/min [36]). One way to increase
the eﬀectiveness of ocular delivery systems would, therefore, be to
design materials which can remain on the corneal surface for extended
timeframes. Simultaneously, these drops would need to deliver ther-
apeutic levels of active drugs, locally or to the posterior segment. Such
materials, in the form of lenses have been widely investigated, where
the synthetic lens swells in the presence of water subsequently loading
with targeted therapeutics [37–39]. Controlled delivery can then be
achieved by tailoring diﬀusion of the molecules from the lens to the
eye, once applied. Although promising the use of contact lenses for drug
delivery has not taken hold, commonly due to their application to in-
fected or otherwise damaged eyes, exacerbating the condition [40].
Therefore, resorbable structured gels or ﬂuid gels, are gaining attention.
Such structuring allows for materials such as gellan to be formed into a
ﬂowable material exhibiting similar optical properties to unmodiﬁed
gels. The inserts to Fig. 1C visually illustrate the properties of a ﬂuid
gel, whereby on inversion in the absence of shear, i.e. mixing or
shaking, the gel does not ﬂow. However, under force, the system begins
to ﬂow. Such transitions were probed using dynamic, small deformation
oscillatory techniques, measuring the material viscoelasticity (G’ (sto-
rage modulus) and G” (viscous modulus)). The plot in Fig. 1C demon-
strates the strain dependent properties of a typical gellan ﬂuid gel. At
low strains, within the linear viscoelastic region (LVR), G′ dominates G”
highlighting a solid-like system [41]. At larger strains a decrease in G′ is
observed as the weak interactions between the ribbon-like network
(seen in the light microscopy image Fig. 1A) become cleaved, allowing
the system to untangle and ﬂow. This transition from solid to liquid like
behaviour, eﬀectively increases the retention time of the gel upon the
eyes’ surface, forming a soft structure that becomes slowly removed by
blinking.
As previously described, tailoring of the ﬂuid gel properties can be
controlled during the processing stage. Here the ﬂuid gels were pro-
duced on a rheometer, whereby the formulations can be characterized
in real time, during processing (Fig. 1D). Fig. 1D demonstrates the
change in viscosity as the system is forced through the gelation process
under shear for 0.9% w/v gellan systems crosslinked using: 2.5mM,
5mM and 10mM NaCl. As the temperature is lowered a rapid increase
in viscosity is observed resulting from the gelation of the gellan hy-
drocolloid, until a maximum viscosity is reached (Tmax). Beyond this
point no further structuring is observed, as illustrated by the plateau in
viscosity. The ﬂow proﬁles indicate a salt dependency for both the onset
of gelation and ﬁnal viscosity. The onset of gelation increased as a
function of the salt concentration, shifting to higher temperatures.
Fig. 1. Micrograph illustrating the ﬂuid gel structure
using light microscopy (A). Images illustrating a
Gellan Gum ﬁlm, pre- and post-rehydration in PBS
(B). Strain sweep obtained at 1 Hz for a 0.9% w/v
gellan ﬂuid gel crosslinked using 5mM NaCl. Inserts
show photos demonstrating the ﬂow of a ﬂuid gel
before and after shear is applied to the sample. Shear
can be applied by either mixing or shaking of the
tube, which disrupts the weak interactions between
gelled ribbons (C). Graph demonstrating the forma-
tion of ﬂuid gels with various concentrations of NaCl
in real time; as temperature decreases the viscosity of
the system increases as the gellan ﬂuid gel is formed
(D).
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However, the inverse correlation was observed for the ﬁnal gel visc-
osities (it is important to note that viscosity values obtained at 450 s−1,
20 °C are within the shear thinning region, as such are much higher at
lower shear rates (data not presented)). Enhanced handling properties,
coupled with enhanced stability at previously reported corneal surface
temperatures [42], suggest that the ﬂuid gel formulation containing
10mM NaCl was the best to investigate further in this study.
3.2. Decorin release from gellan ﬁlms and ﬂuid gels
The release of decorin from both gellan ﬁlms and ﬂuid gels was
evaluated over 3 h using a dynamic system, whereby the samples were
placed in culture media at 37 °C and agitated on a shaker at 250 rpm. At
sampling points, the eluting solution was removed and replaced with
fresh media to simulate absorption within the eye. The diﬀerence in
release proﬁles between the two systems can be clearly seen in Fig. 2A,
where decorin concentration gradients nearing equilibrium are reached
much more rapidly within the ﬂuid gel system (ca. 0.5 h) compared to
the ﬁlm (ca. 1 hr). It is argued that the extent and rate of decorin re-
leased is controlled by morphological changes arising from drying, re-
sulting in glass-to-rubber transitions associated with rehydration; here a
greater extent of swelling/structuring occurs as ﬁlms become rehy-
drated (Fig. s2), leading to an eﬀective reduction in the elution media,
preventing as much protein leaving the ﬁlm [43]. Accompanying ki-
netics were therefore observed to be a function of the gelled micro-
structure, with constant (close to zero-order, release index=0.86)
elution of decorin from the gellan ﬁlms and release for the ﬂuid gel
much closer to Fickian with a release index of 0.66 (Fig. 2b) [44]. As
such, cumulative proﬁles showed 25% and 45% release over the 3 h for
the ﬁlm and ﬂuid gel respectively. Therefore, enhanced release proﬁles
for the ﬂuid gel systems when compared to the ﬁlms prompted further
studies in vitro, in and ex vivo.
3.3. Fluid gel-decorin activity in vitro, using primary human corneal
ﬁbroblasts
Gellan ﬂuid gel toxicity was tested in 2D using human corneal ﬁ-
broblast (hCF) cultures, characterized via MTT assay. Cultures with and
without ﬂuid gels didn't provoke toxic eﬀects to the cells over the 12
days of study (Fig. 3A). Furthermore, no signiﬁcant diﬀerences between
ﬂuid gels with and without decorin (Fig. 3B) were observed in cultures
stained with Calcein AM and propidium iodide (PI), used as an in-
dicator for live and dead cells respectively. Collagen deposition was
assessed using a semi-quantitative staining, Sirius Red, which binds the
total collagen expressed by the hCF cultures post TGF- β1 treatment.
Reduced collagen deposition was seen in the hCF cultures treated with
decorin containing gellan ﬂuid gel after 7 and 12 days of culturing. This
was when compared to hCF cultures treated with just ﬂuid gel (Fig. 3C).
The stain was further dissolved and measured using UV spectroscopy at
550 nm, a signiﬁcant (p < 0.05) reduction in absorbance was observed
at day 12, as a function of the decorin preventing the corneal cells from
depositing collagen.
3.4. Fluid gel transparency and retention on the ocular surface
Transparency of the gellan ﬂuid gels was determined using UV
spectroscopy over 35 days, illustrated by Fig. 4A, showing optical sta-
bility at 90% transmittance throughout the study. Following optical
clarity studies, ﬂow and re-structuring of gellan ﬂuid gel, that is, the
time between the removal of the shear force (during application) and
re-thickening, was monitored using freshly enucleated porcine eyes.
The gel was applied topically to the cornea, inducing liquid-like be-
haviour. Immediate thickening of the gel was observed on contact with
the ocular surface, demonstrating a thickening time which was lower
than experimentally obtainable in this manner (< 1 s) (Fig. 4B).
The thickening of the gel was further tested in vivo, whereby 50 μl of
the gel was dropped on the surface of anaesthetised rat eyes and
clearance time evaluated (Fig. 5A). A thin layer of gellan ﬂuid gel re-
mained on the surface of the rat cornea after 90min (Fig. 5C). When
compared to PBS, the retention time was greatly enhanced, as the PBS
cleared within the ﬁrst 60min (Fig. 5B). The mean thickness of the gel
was 1000 μmat t0 and reduced to 50 μm after t120. However, the PBS
drop had a mean thickness of 800 μmat t0 and could no longer be
observed at the 60min evaluation point post-application. Interestingly,
when comparing the spreading of the ﬂuid gel using thickness mea-
surements centrally (90° - See Fig. 5C), temporally (135°) and nasally
(45°) across the eye's surface, there was no signiﬁcant diﬀerence. This
indicates an even coverage as the gel ﬂowed and spread upon the ocular
surface for 2 h (Fig. 5D and E).
3.5. Fluid gel-decorin activity assessed ex-vivo (organ culture model)
An ex-vivo corneal wound healing model, demonstrating corneal re-
epithelization, was used to evaluate the bio-activity of the decorin
system. Histology, using H&E staining, illustrated the complete removal
of the epithelium across a 5mm diameter wound (Fig. 6A). Application
of the decorin in the absence of the gel carrier demonstrated that, even
at signiﬁcantly high concentrations (1 mg/ml (Fig. 6B) and 3mg/ml
(Fig. 6C)), decorin had no eﬀect in re-epithelialisation of the cornea,
potentially as a function of the extent of injury. However, data shown
for abrasion and treatment using gellan ﬂuid gel containing decorin
resulted in stimulated re-epithelialisation within 2 days of treatment
(Fig. 6D).
The ex vivo rat model of corneal injury shows delamination and full
thickness epithelial debridement across a∼5 mm diameter wound. The
corneal epithelium is stained blue and the underlying corneal stromal
Fig. 2. Decorin release from the two diﬀerent gellan for-
mulations, ﬁlms and ﬂuid gels. Fluid gels exhibited in-
creased release of decorin 35 μg/ml when compared to
the ﬁlms (20 μg/ml) across the same timeframe, 3 h (A).
Cumulative % release of decorin, demonstrating changes
is release for both the ﬂuid gel and gellan ﬁlm. Equations
for lines of best ﬁt are as follows: =y x0.26 0.86 (R2=0.99)
and =y x1.5 0.66 (R2=0.99), for the ﬁlm and ﬂuid gel
respectively (B).
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layers are stained in pink. (A). H&E staining of a completely debrided
cornea treated with 1.0 mg/ml of decorin (B) and 3.0 mg/ml Decorin
only, insert shows the high-magniﬁcation view of the respective stroma
(The stroma is stained in pink, however, no epithelial cells (blue stained
cells) were present on the surface of the cornea, conﬁrming the absence
of re-epithelisation) (C). Images illustrating re-epithelialisation in epi-
thelia abraded rat eyes, when treated with gellan ﬂuid gels with and
without decorin, ﬂuorescein staining was quantiﬁed using ImageJ (D).
An increase in re-epithelialisation occurred in samples treated with
gellan Fluid gel + decorin, shown by a reduction in ﬂuorescein staining
to 18% after 4 days when treated the gel containing decorin when
compared to gellan ﬂuid gels without decorin (E).
Corneal re-epithelialisation was determined by measuring the sur-
face area of ﬂuorescent staining on the ocular surface, with respect to
Day 0. Fluorescent staining on the day of injury was measured at 100%
for both treatment groups. An approximate 40% reduction in ﬂuores-
cence was seen at Day 2 of organ culture, in both treatment groups with
and without decorin. A further signiﬁcant (p < 0.05) reduction in
staining at Day 4 was observed, whereby the cultures containing dec-
orin were reduced to 15%, in comparison to the treatment group
without decorin, still showing 48% ﬂuorescence remaining (Fig. 6F).
4. Discussion
Topical administration of ophthalmic drugs remains a popular
choice of therapy for the treatment of corneal diseases, due to their ease
of use and patient compliance. However, ocular bioavailability is poor
due to rapid clearance rates, leading to increased levels of reapplication
e.g. often hourly, day and night. Often the primary strategy to improve
ocular bioavailability after topical administrations, is to promote the
retention of therapeutics or biologicals upon the corneal surface.
Currently, this is achieved by injections to the peri-ocular depot [45],
increasing contact time though viscosity modiﬁcation or vehicles
[46,47], or applying delivery devices such as therapeutic bandages (e.g
contact lenses) [39]. However, very few physical dressings have been
clinically approved, as prolonged wear can often further damage or
result in further complications, for example microbial keratitis [40].
Application of corneal sheet dressings, for example amniotic mem-
brane, often requires surgery due to required suturing. Although such
dressings have been shown to work [7], they are less favourable
therapies due to reasons such as, surgical intervention, risk of trans-
plant related diseases and availability.
Recently, the development of micro-structured hydrogel systems,
called ﬂuid gels, have been widely studied as drug-delivery systems for
various biomedical applications [48]. Fluid gels can be developed from
Fig. 3. The eﬀect of toxicity in primary human
corneal ﬁbroblasts (hCF), cultured on tissue
culture plastic only (TCP) and TCP with the ad-
dition of decorin loaded ﬂuid gel. MTT analysis
showed no signiﬁcant diﬀerence in the TCP or
gellan ﬂuid gel samples over 12 days (n= 3,
error bars show one standard deviation) (A).
Fluorescent images of Calcein AM (green) and PI
(red) staining, indicative of live and dead cells
respectively (B). Micrographs demonstrating
Sirius Red staining, shows total collagen de-
position in hCF cultures treated using gellan
ﬂuid gel with/without decorin (C). Semi-quan-
titive analysis of collagen production in hCF
cultures (n= 5, error bars show one standard
deviation) (D). (For interpretation of the refer-
ences to colour in this ﬁgure legend, the reader is
referred to the Web version of this article.)
Fig. 4. Gellan ﬂuid gels demonstrated 90% transpar-
ency when tested over 35 days using UV spectroscopy
(A). Setting time of the gels were tested on freshly
enucleated porcine eyes, whereby the gel was dropped
on the ocular surface and thickening time was de-
termined. Re-structuring of the gel occurred almost
instantaneously (< 1 s) after application (B).
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Fig. 5. To evaluate the in vivo clearance of the gellan ﬂuid gel from the pre-corneal space, 40 μl of the ﬂuid gel was dropped on to the surface of anaesthetised rat eyes
and imaged using OCT (optical coherence tomography) (A). Mean drop thicknesses for both PBS and ﬂuid gels as a function of time were evaluated, demonstrating
that only the ﬂuid gel systems persist throughout the whole experiment (* = p < 0.006, ** = p < 0.004, and *** = p < 0.001 vs PBS + Decorin eye drops) (B).
Typical representation of OCT images used to quantify eye drop layer thickness (C). Quantiﬁcation using ImageJ of the mean thickness of OCT images (C) of eye
drops at 30min intervals up to 120 min at diﬀerent regions of corneal surface (45° (nasal, ‘N’), 90° (central, ‘C’), 135° (temporal, ‘T’) (inserted lines to guide the eye in
“C”) (D and E).
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various natural biopolymers including both polysaccharides and pro-
teins [29]. This study investigated a commonly used thickening agent,
gellan gum, as the gelling polymer to make ﬂuid gels that house dec-
orin, for delivery to the ocular surface. The preparation of ﬂuid gels
requires a cooling process, whereby a ﬁxed shear rate is applied to the
hydrocolloid sol, resulting in for the formation on micro-gelled “ribbon-
like” matrices, which are largely dispersed in an un-gelled medium
[23,49]. This hydrogel system exhibits reversible weak gel to liquid-like
transitions upon external stimuli such as syringing, allowing applica-
tion to the ocular surface. This forms a temporary occlusive bandage
that can dynamically change to the eye's blinking environment, retaring
elimination from the ocular surface and enhance retention.
Based on the mechanical ﬁndings, the gellan ﬂuid gels exhibit ex-
cellent potential as a wound dressing. The dressing is easy to apply,
reversibly shear thinning to provide an occlusive transparent layer.
Initial in vivo studies highlight the ﬂuid gels' retention to the ocular
surface, demonstrating visible ﬂuid gel layers for up to 2 h on a rodent's
eye. Gels exhibited uniform layers, having spread across the corneal
surface, heterogeneously thinning (thinner in the centre to the per-
ipheries) across the 2 h as it became cleared from the tear ﬁlm. While
this is expected in a rodent model, due to the size of the drop and the
curvature of the eyeball, it doesn't present any signiﬁcant problems for
the sustained release of the decorin, still remaining occlusive over the
cornea.
The unique suspension hysteresis makes these suspended hydrogels
solutions highly attractive for use in ocular drug-delivery applications.
Release proﬁles for decorin loaded ﬂuid gels were compared to the
gellan ﬁlms, a comparative mimetic to in situ gelled therapies.
Diﬀerences in release between the two systems were observed, depen-
dent on the microstructure. Shear applied during processing and re-
sulting particulate suspension enhanced the rate of release, as expected
due to the subsequent increase in surface area. Additionally, a transi-
tion from zero order to kinetics more closely controlled by Fickian
diﬀusion were observed when analysed using a simple power function
described by Ritger et al. (1987) [44]. Results agreed with similar
studies probing the release from in situ gelation of gellan and eye drops,
where typical zero-order plots were obtained for the gellan gel, redu-
cing in the release index for the drop system [50]. It is argued that the
relatively large release index for the gellan ﬂuid gel (0.66), in com-
parison to those previously shown for pure Fickian release (0.43–0.5,
for slabs spheres and cylinders [44]), are a function of the ribbon like
morphology and ability to entwine forming a weak network between
particles. This ultimately resulted in a much more rapid and controlled
release for the ﬂuid gels in comparison to the gellan ﬁlms, leading to an
eye drop system with much higher therapeutic dosing within the
timescale associated ocular retention. Thus, the controlled behaviour of
release allows the eye drop to give sustained dosing, using repeat ap-
plications at clinically relevant administrations (3–4 times daily), and
improving bio-eﬃciency.
Bio-eﬃciency and activity were addressed both in vitro and ex vivo
probing cytotoxicity and the system's ability to heal the cornea. Both
the gellan ﬂuid gel and the decorin showed good compliance with cells,
as expected; having already been approved for both medicinal and food
uses (gellan), and successfully proven in multiple animal models (dec-
orin), for the reduction in scarring [32,51]. Semi-quantitive analysis of
collagen production using Picro Sirius Red staining highlighted the ef-
ﬁcacy of the decorin in vitro, signiﬁcantly reducing the degree of col-
lagen deposition, corresponding with the current understanding in lit-
erature [54,55]. Such control over the collagen production is facilitated
through strong decorin-collagen interactions. Naturally decorin ‘dec-
orates’ the ﬁbrils, both playing key roles in both spacing and the reg-
ulation of growth factors, through sequestration [53]. In turn, con-
trolled lay down of collagen is achieved which ultimately directs ﬁbre
alignment and prevents the formation scarred tissue [52].
Further understanding of the decorin loaded ﬂuid gel eﬃcacy was
achieved using a previously, well-established, ex vivo organ culture
model for ocular healing, whereby a corneal keratectomy was applied
to a rodent eye and visualised using staining [56–59]. The model is
based on a clinically employed technique of apply a ﬂuorescein stain to
the ocular surface which directly exposes corneal debridement, with
staining proportional to the damaged epithelial surface. Decorin only
controls were applied using PBS as a carrier to mimic conventional eye
drops. Haematoxylin and eosin histology showed no signs of healing
with an absence of re-epithelialisation at both decorin concentrations
studied, 1 and 3mg/ml. It is proposed that in these cases, although no
blinking mechanism is present, the combination of drying and low
Fig. 6. Histological image of typically H&E stained rats' cornea, illustrating complete epithelial debridement.
G. Chouhan, et al. Biomaterials 210 (2019) 41–50
48
viscosity of the PBS is insuﬃcient to keep the decorin upon the curved
surface of the cornea. Application of the ﬂuid gel vehicle in the pre-
sence of the active, however, increased epithelial closure across the
cornea, shown via ﬂuorescein staining, as a result of the decorin's
matrikine properties [60], providing modiﬁcation to the cellular en-
vironment. When compared to the ﬂuid gel only control, no change in
would closure was observed with no reduction is stained areas ob-
served. Such observations reinforced the requirement of a delivery
vehicle, augmenting the retention needed for suﬃcient bioavailability
and a therapeutic response. Furthermore, the gellan device appeared to
be inert, only enhancing wound healing by retaining the therapeutic.
In summary, this study has highlighted the use of gellan ﬂuid gel as
a potential vehicle for the delivery and retention of therapeutics upon
the ocular surface. The novelty within this vehicle is derived through
the processing of the polymer as it goes through its sol-gel transition,
resulting in a system that can dynamically transition between solid-
liquid-solid to provide sustained delivery with enhanced longevity in
comparison to typically used in situ gelation. Furthermore, the system
has demonstrated its bio-eﬃcacy in in vitro, vivo and ex vivo models. In
doing so, enhanced retention has proved essential to gaining a ther-
apeutic response providing an ideal system for ease of application and
therapeutic activity.
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